FFRangio System vs Discovery MI Gen2
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
The FFRangio System is an interventional cardiology tool that uses AI for wire-free FFR guidance to optimize PCI decisions for coronary artery disease. In contrast, the Discovery MI Gen2 is a diagnostic PET/CT imaging system that leverages deep-learning AI for superior image quality and lesion detection across oncology, neurology, and cardiology. While both utilize AI in cardiology, they serve distinct purposes: one for treatment guidance and the other for advanced diagnostic imaging.
Choose FFRangio System if…
Choose the FFRangio System if your primary need is real-time, non-invasive physiological assessment of coronary artery disease directly within the cath lab. This tool is ideal for interventional cardiologists seeking to optimize PCI decisions and confirm treatment efficacy without the use of invasive pressure wires or vasoactive drugs, leveraging AI for quick angiogram analysis and lesion impact assessment.
View FFRangio System →Choose Discovery MI Gen2 if…
Choose Discovery MI Gen2 if your focus is on advanced, high-sensitivity diagnostic imaging across oncology, neurology, and cardiology. This system is best suited for institutions requiring superior image quality, improved small lesion detectability, and precise quantitative measurements for disease staging and treatment monitoring, all while benefiting from reduced scan times and radiation dose through deep-learning AI.
View Discovery MI Gen2 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FFRangio System | Discovery MI Gen2 |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Starts at $15,500.00 |
| Deployment | SaaS, on-prem, hybrid | On-premise |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FFRangio System | Discovery MI Gen2 |
|---|---|---|
| Name | FFRangio System | Discovery MI Gen2 |
| Company | CathWorks | GE HealthCare |
| Description | The CathWorks FFRangio System delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease. | GE HealthCare's Discovery MI Gen2 is a next-generation digital PET/CT system that leverages deep-learning AI, high sensitivity, and advanced motion correction to deliver superior diagnostic imaging for oncology, neurology, and cardiology. |
| Tagline | A New Era in Coronary Physiology | Next generation. Even more in sight. |
| Primary Categories | Cardiology AI, Surgical AI | Cardiology AI, Neurology AI, Oncology AI |
| Primary Specialties | Cardiology | Nuclear Medicine, Oncology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring FFRangio System and Discovery MI Gen2.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
The CathWorks FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease. It offers real-time FFRangio values and advanced insights for quick decision-making. In contrast, GE HealthCare's Discovery MI Gen2 is a digital PET/CT system that delivers superior diagnostic imaging for cardiology, as well as oncology and neurology, intended for imaging the heart to assess metabolic and physiologic function.
The FFRangio System uses artificial intelligence to aid in quick angiogram analysis and to obtain physiologic information from routine angiograms, combining AI with advanced computational science to deliver real-time FFRangio values. Discovery MI Gen2 leverages deep-learning AI for TrueFidelityu2122 image reconstruction, which combines low-dose CT with a classic image texture. It also incorporates AI for advanced motion correction with its MotionFree digital respiratory motion management solution.
The FFRangio System is designed to be wire-free and drug-free, eliminating the need for invasive pressure wires or hyperemic agents, which aims to reduce patient discomfort and potential complications during coronary artery disease assessment. Discovery MI Gen2 is a diagnostic imaging system that aims to improve patient experience through features like reduced scan times, reduced injected dose, and an automated patient positioning system (Auto IN), offering high-resolution imaging with enhanced comfort and safety.
The FFRangio System is specifically designed for assessing coronary artery disease (CAD) and optimizing percutaneous coronary intervention (PCI) decisions, helping to determine the severity of blockages and the need for interventions like stent placement. Discovery MI Gen2 provides diagnostic imaging for a broader range of cardiac applications, including the study of myocardial perfusion and function, alongside its uses in oncology and neurology for accurate disease diagnosis and staging.
The FFRangio System is ISO 27001 certified for information security and ISO 13485 certified, and while HIPAA compliance is not explicitly stated on its public website, it handles protected health information (PHI). GE HealthCare generally operates under HIPAA-compliant agreements, and the Discovery MI Gen2's process follows GDPR, HIPAA, NIST 800-53, NIST 800-30, and ISO 27001 requirements, making it likely HIPAA compliant as a medical device handling PHI.